Unity Biotechnology Inc (STU:9U90)
€ 1.308 -0.008 (-0.61%) Market Cap: 22.57 Mil Enterprise Value: 9.93 Mil PE Ratio: 0 PB Ratio: 0.98 GF Score: 30/100

UNITY Biotechnology Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 03, 2021 / 06:20PM GMT
Release Date Price: €59.45 (-2.94%)
Georgi Nenov Yordanov
Cowen and Company, LLC, Research Division - Specialty Pharma Associate

Hi, everyone. Welcome back to Cowen's 41st Healthcare Conference. I am really excited to introduce UNITY Biotech, and Anirvan and Lynne on the management team.

Anirvan Ghosh
Unity Biotechnology, Inc. - CEO & Director

Thanks, Georgi. I'm happy to provide an update on UNITY's platforms and programs. I'm Anirvan Ghosh, CEO of UNITY; and we also have Lynne Sullivan, our CFO, on the call.

Matthew, if you could forward a couple of slides. I'll give an overview of where UNITY is. At UNITY, we're developing therapies to slow, halt or reverse diseases of aging. Our primary interests are in ophthalmology and neurology. In ophthalmology, we're focused on DME, diabetic retinopathy and AMD. In neurology, a number of neurologic indications, including Alzheimer's, FTD and PSP.

The primary mechanism that we are targeting is cellular senescence, and I'll talk a little bit more about that in a minute. But we also have programs that are based on other aging

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot